CFD's zijn complexe instrumenten en houden vanwege de hefboomwerking een hoog risico in op grote verliezen. 70% van de particuliere beleggers verliest geld bij de handel in CFD's met deze aanbieder.U moet nagaan of u wel degelijk begrijpt hoe CFD's werken en of u zich het hoge risico op geldverlies kunt veroorloven. Raadpleeg onze risicoverklaring
Vitrolife is a global company contributing products within the IVF (in vitro fertilisation) field. Founded in 1994, Vitrolife was one of the first companies providing IVF laboratories with high quality ready-to-use culture media. Today its portfolio holds products all the way from oocyte retrieval to transfer of the embryo. The company collaborates with several researchers within the field of ART, both universities and clinics. Vitrolife has approximately 370 employees and its headquarters are located in Sweden with additional locations and production facilities in more than ten countries worldwide. The company has sales in more than 110 countries. The Vitrolife share is listed on the NASDAQ Stockholm, Nordic Mid Cap. To learn the latest Vitrolife (VITR) share price, follow Capital.com.
Dit zijn onze 4- & 5-sterrenbeoordelingen. Om te voldoen aan de GDPR-vereisten en de privacy van de gebruikers te waarborgen, zijn hun specifieke gegevens bewust anoniem gemaakt.